Haemophilus influenzae infection

Revision as of 18:58, 5 December 2012 by Aarti Narayan (talk | contribs)
Jump to navigation Jump to search
Haemophilus influenzae on a blood agar plate

WikiDoc Resources for Haemophilus influenzae infection

Articles

Most recent articles on Haemophilus influenzae infection

Most cited articles on Haemophilus influenzae infection

Review articles on Haemophilus influenzae infection

Articles on Haemophilus influenzae infection in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Haemophilus influenzae infection

Images of Haemophilus influenzae infection

Photos of Haemophilus influenzae infection

Podcasts & MP3s on Haemophilus influenzae infection

Videos on Haemophilus influenzae infection

Evidence Based Medicine

Cochrane Collaboration on Haemophilus influenzae infection

Bandolier on Haemophilus influenzae infection

TRIP on Haemophilus influenzae infection

Clinical Trials

Ongoing Trials on Haemophilus influenzae infection at Clinical Trials.gov

Trial results on Haemophilus influenzae infection

Clinical Trials on Haemophilus influenzae infection at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Haemophilus influenzae infection

NICE Guidance on Haemophilus influenzae infection

NHS PRODIGY Guidance

FDA on Haemophilus influenzae infection

CDC on Haemophilus influenzae infection

Books

Books on Haemophilus influenzae infection

News

Haemophilus influenzae infection in the news

Be alerted to news on Haemophilus influenzae infection

News trends on Haemophilus influenzae infection

Commentary

Blogs on Haemophilus influenzae infection

Definitions

Definitions of Haemophilus influenzae infection

Patient Resources / Community

Patient resources on Haemophilus influenzae infection

Discussion groups on Haemophilus influenzae infection

Patient Handouts on Haemophilus influenzae infection

Directions to Hospitals Treating Haemophilus influenzae infection

Risk calculators and risk factors for Haemophilus influenzae infection

Healthcare Provider Resources

Symptoms of Haemophilus influenzae infection

Causes & Risk Factors for Haemophilus influenzae infection

Diagnostic studies for Haemophilus influenzae infection

Treatment of Haemophilus influenzae infection

Continuing Medical Education (CME)

CME Programs on Haemophilus influenzae infection

International

Haemophilus influenzae infection en Espanol

Haemophilus influenzae infection en Francais

Business

Haemophilus influenzae infection in the Marketplace

Patents on Haemophilus influenzae infection

Experimental / Informatics

List of terms related to Haemophilus influenzae infection

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Hib disease

Overview

Infection with the bacterium Haemophilus influenzae type b (Hib) can result in meningitis and other severe infections (e.g., pneumonia, bacteremia, cellulitis, septic arthritis, and epiglottitis) primarily among infants and children <5 years of age.

Epidemiology and Demographics

During 1980-1990, incidence was 40-100/100,000 children < 5 years old in the United States. Due to routine use of the Hib conjugate vaccine since 1990, the incidence of invasive Hib disease has decreased to 1.3/100,000 children. However, Hib remains a major cause of lower respiratory tract infections in infants and children in developing countries where vaccine is not widely used.

Invasive Hib disease is endemic throughout the world. In countries that have achieved high coverage with routine Hib vaccination programs, Hib disease has become rare. In 2004, most countries in Western Europe, South America, and Central America had initiated routine Hib vaccination (http://www.who.int/mediacentre/factsheets/fs294/en/). However, Hib disease remains common in many developing countries and is estimated to cause 2-3 million cases of serious disease in young children annually.

Hib disease is uncommon in anyone 5 years of age or older. Hib meningitis has a case-fatality ratio of 5-10% in the United States even with initiation of early antimicrobial therapy. As a result of the widespread use of conjugate Hib vaccines, the disease is now uncommon in the United States and is seen primarily in infants too young to be vaccinated and unvaccinated children. In 2004, the estimated annual incidence of Hib was 0.15 cases per 100,000 in children younger than 5 years of age.

Trends

Since licensure of conjugate vaccines for infants (1990) and children (1987), rates of disease among children <5 years old have declined by more than 95% in the United States, while rates for adults have remained stable. However, rates of disease among Alaskan natives remain higher than elsewhere in the United States.

Risk Factors

Infants and young children, household contacts, and day-care classmates are at higher tisk of aquiring Haemophilus influenzae serotype B infection.

Risk for travelers

Unvaccinated infants and children aged less than 5 years who travel may be at risk for serious Hib disease, especially if traveling to a country that does not use Hib vaccine. In addition, adults who have been splenectomized have an increased risk of infections.

Pathophysiology & Etiology

Etiologic agent

Haemophilus influenzae serotype b.

Transmission

Direct contact with respiratory droplets from nasopharyngeal carrier or case patient.

Natural History

Haemophilus influenzae, formerly called Pfeiffer's bacillus or Bacillus influenzae, is a non-motile Gram-negative coccobacillus first described in 1892 by Richard Pfeiffer during an influenza pandemic. It is generally aerobic, but can grow as a facultative anaerobe. H. influenzae was mistakenly considered to be the cause of the common flu until 1933, when the viral etiology of the flu became apparent. Still, H. influenzae is responsible for a wide range of clinical diseases.

Because of its small genome, H. influenzae became the first free-living organism with its entire genome sequenced. Its genome consists of 1,830,140 base pairs of DNA and contains 1740 genes. The method used was Whole genome shotgun. The sequencing project, completed and published in Science in 1995, was conducted at The Institute for Genomic Research.

Diagnosis

History and Symptoms

Before the availability of the Haemophilus influenzae serotype b (Hib) conjugate vaccine in the United States and other industrialized countries, more than one-half of Hib cases presented as meningitis with fever, headache, and stiff neck. The remainder presented as cellulitis, arthritis, or sepsis. In developing countries, Hib is still a leading cause of bacterial pneumonia deaths in children.

Risk Stratification and Prognosis

3%-6% of cases are fatal; up to 20% of surviving patients have permanent hearing loss or other long-term sequelae.

Treatment

Specific parenteral antibiotic treatment is necessary for invasive Hib disease, and immediate airway stabilization is necessary for epiglottitis. Antibiotic prophylaxis with rifampin is indicated for all household contacts in the following circumstances: households with a contact aged 4 years or younger who is unimmunized or underimmunized, households with a child aged younger than 12 months who has not received the primary series, and households with an immunocompromised child. Chemoprophylaxis is not recommended for pregnant women or for child care contacts with a single index case, but the children’s vaccination history should be reviewed to ensure completion of the recommended schedule of Hib conjugate vaccine. A 4-day course of rifampin eradicates Hib carriage from the pharynx in approximately 95% of carriers.

Primary Prevention

Haemophilus Influenzae Type b (Hib) Vaccine

Future or Investigational Therapies

Challenges

Elimination of persistent Hib disease in the United States. Currently available conjugate vaccines differ in immuno-genicity in very young children and possibly in duration of antibody persistence, raising questions about long-term efficacy (>5 years), optimal use, and schedules. Monitoring the possible emergence of disease due to other serotypes. Problems with serotyping of H. influenzae in state health departments. Development of rapid molecular assays for detection and molecular subtyping of all Hi strains. The cost of Hib conjugate vaccines has limited their use in developing countries even though Hib is a major cause of morbidity and mortality.

Opportunities

Evaluating the characteristics of Hib vaccines associated with prevention of carriage and invasive disease will facilitate application of this technology to development of conjugate vaccines for other organisms with polysaccharide capsules (such as the meningococcus, pneumococcus, and group B streptococcus). Further evaluation of herd immunity effects may lead to insight into vaccination strategies that optimize protection against invasive disease and transmission of Hib organisms.

References

  1. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/histoplasmosis_g.htm
  2. http://en.wikipedia.org/wiki/Haemophilus_influenzae
  3. http://wwwn.cdc.gov/travel/yellowBookCh4-FluMeningitis.aspx

Acknowledgements

The content on this page was first contributed by: C. Michael Gibson, M.S., M.D.


Template:WH Template:WikiDoc Sources